Is FDA Stifling Your Innovations? What Can You Do?
With the current challenges in the U.S. regulatory pathway, med tech companies are forced to explore other avenues to bring products to market. Many companies are looking outside of the U.S. for their initial launch.
The panel will discuss the pros and cons of launching a new medical innovation outside of the U.S. What drove the decision? What steps did they take? And what lessons did they learn?
- Mike Oliver, President and CEO, SpectraScience
- Allan Rozenberg, PhD, Chief Operating Officer, Benechill
- Richard Strobridge, CEO, Entra Health Systems